S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
The Odds Are High Costco Will Declare a Special Dividend Soon 
The Strategic Gold Play You Haven't Heard About (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Stock market today: Global shares mostly fall over China worries
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
Video: Jack in the Box Employee Shoots at Customer Over Alleged Missing Curly Fries, Family Files Lawsuit
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Low Beta Stocks To Offset A Possible Hard Landing
3 Mid-Cap Momentum Plays to Ride Into Q4
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
The Odds Are High Costco Will Declare a Special Dividend Soon 
The Strategic Gold Play You Haven't Heard About (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Stock market today: Global shares mostly fall over China worries
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
Video: Jack in the Box Employee Shoots at Customer Over Alleged Missing Curly Fries, Family Files Lawsuit
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Low Beta Stocks To Offset A Possible Hard Landing
3 Mid-Cap Momentum Plays to Ride Into Q4
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
The Odds Are High Costco Will Declare a Special Dividend Soon 
The Strategic Gold Play You Haven't Heard About (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Stock market today: Global shares mostly fall over China worries
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
Video: Jack in the Box Employee Shoots at Customer Over Alleged Missing Curly Fries, Family Files Lawsuit
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Low Beta Stocks To Offset A Possible Hard Landing
3 Mid-Cap Momentum Plays to Ride Into Q4
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
The Odds Are High Costco Will Declare a Special Dividend Soon 
The Strategic Gold Play You Haven't Heard About (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Stock market today: Global shares mostly fall over China worries
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
Video: Jack in the Box Employee Shoots at Customer Over Alleged Missing Curly Fries, Family Files Lawsuit
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Low Beta Stocks To Offset A Possible Hard Landing
3 Mid-Cap Momentum Plays to Ride Into Q4
NASDAQ:CRNX

Crinetics Pharmaceuticals (CRNX) Stock Forecast, Price & News

$28.03
-0.66 (-2.30%)
(As of 09/27/2023 ET)
Compare
Today's Range
$27.24
$29.21
50-Day Range
$15.97
$30.59
52-Week Range
$15.23
$31.00
Volume
782,298 shs
Average Volume
3.15 million shs
Market Capitalization
$1.53 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.00

Crinetics Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
60.5% Upside
$45.00 Price Target
Short Interest
Healthy
7.44% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.96mentions of Crinetics Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$779,189 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.68) to ($3.85) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.70 out of 5 stars

Medical Sector

105th out of 975 stocks

Pharmaceutical Preparations Industry

32nd out of 458 stocks


CRNX stock logo

About Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California.

CRNX Price History

CRNX Stock News Headlines

Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
What's Going On With Crinetics Pharmaceuticals Stock?
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
Why Shares of Crinetics Pharmaceuticals Are Jumping Monday
9 Analysts Have This to Say About Crinetics Pharmaceuticals
See More Headlines
Receive CRNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRNX Company Calendar

Last Earnings
8/08/2023
Today
9/28/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRNX
Fax
N/A
Employees
210
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$45.00
High Stock Price Forecast
$56.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+60.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-163,920,000.00
Net Margins
-3,804.10%
Pretax Margin
-3,804.10%

Debt

Sales & Book Value

Annual Sales
$4.74 million
Book Value
$5.88 per share

Miscellaneous

Free Float
50,859,000
Market Cap
$1.53 billion
Optionable
Not Optionable
Beta
0.85
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. R. Scott Struthers Ph.D. (Age 61)
    Founder, Pres, CEO & Director
    Comp: $870.69k
  • Dr. Stephen F. Betz Ph.D. (Age 57)
    Founder & Chief Scientific Officer
    Comp: $618.58k
  • Mr. Marc J. C. Wilson (Age 44)
    Chief Financial Officer
    Comp: $585.54k
  • Mr. James Hassard (Age 57)
    Chief Commercial Officer
    Comp: $513.34k
  • Dr. Dana Pizzuti M.D. (Age 67)
    Chief Devel. Officer
    Comp: $493.62k
  • Mr. Jeff E. Knight (Age 52)
    Chief Operating Officer
  • Ms. Garlan Adams
    Gen. Counsel & Corp. Sec.
  • Ms. Adriana Cabre M.B.A.
    Chief HR Officer
  • Dr. Alan S. Krasner M.D. (Age 60)
    Chief Medical Officer
  • Mr. Kevin Capps
    Head of Intellectual Property













CRNX Stock - Frequently Asked Questions

Should I buy or sell Crinetics Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRNX shares.
View CRNX analyst ratings
or view top-rated stocks.

What is Crinetics Pharmaceuticals' stock price forecast for 2023?

8 brokerages have issued 1-year target prices for Crinetics Pharmaceuticals' shares. Their CRNX share price forecasts range from $33.00 to $56.00. On average, they expect the company's share price to reach $45.00 in the next year. This suggests a possible upside of 60.5% from the stock's current price.
View analysts price targets for CRNX
or view top-rated stocks among Wall Street analysts.

How have CRNX shares performed in 2023?

Crinetics Pharmaceuticals' stock was trading at $18.30 at the start of the year. Since then, CRNX stock has increased by 53.2% and is now trading at $28.03.
View the best growth stocks for 2023 here
.

Are investors shorting Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals saw a decrease in short interest in September. As of September 15th, there was short interest totaling 4,070,000 shares, a decrease of 10.4% from the August 31st total of 4,540,000 shares. Based on an average daily trading volume, of 1,300,000 shares, the days-to-cover ratio is currently 3.1 days.
View Crinetics Pharmaceuticals' Short Interest
.

When is Crinetics Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our CRNX earnings forecast
.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.94) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by $0.09. The company earned $0.99 million during the quarter, compared to the consensus estimate of $5 million. Crinetics Pharmaceuticals had a negative net margin of 3,804.10% and a negative trailing twelve-month return on equity of 61.19%.

What ETF holds Crinetics Pharmaceuticals' stock ?

iShares Micro-Cap ETF holds 121,735 shares of CRNX stock, representing 0.25% of its portfolio.

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an IPO on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Driehaus Capital Management LLC (9.69%), BlackRock Inc. (8.41%), State Street Corp (4.09%), Perceptive Advisors LLC (3.56%), Geode Capital Management LLC (1.81%) and Braidwell LP (1.19%). Insiders that own company stock include Ajay Madan, Coelho Rogerio Vivaldi, Dana Pizzuti, Jeff E Knight, Marc Wilson, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers and Stephen F Betz.
View institutional ownership trends
.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $28.03.

How much money does Crinetics Pharmaceuticals make?

Crinetics Pharmaceuticals (NASDAQ:CRNX) has a market capitalization of $1.53 billion and generates $4.74 million in revenue each year. The company earns $-163,920,000.00 in net income (profit) each year or ($3.41) on an earnings per share basis.

How many employees does Crinetics Pharmaceuticals have?

The company employs 210 workers across the globe.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The official website for the company is www.crinetics.com. The company can be reached via phone at (858) 450-6464 or via email at ir@crinetics.com.

This page (NASDAQ:CRNX) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -